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Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), formerly 
known as autoimmune polyendocrine syndrome type 1, is a paradigm of a monogenic 
autoimmune disease caused by mutations of a gene, named autoimmune regulator 
(AIRE). AIRE acts as a transcription regulator that promotes immunological central 
tolerance by inducing the ectopic thymic expression of many tissue-specific antigens. 
Although the syndrome is a monogenic disease, it is characterized by a wide variability of 
the clinical expression with no significant correlation between genotype and phenotype. 
Indeed, many aspects regarding the exact role of AIRE and APECED pathogenesis still 
remain unraveled. In the last decades, several studies in APECED and in its mouse 
experimental counterpart have revealed new insights on how immune system learns 
self-tolerance. Moreover, novel interesting findings have extended our understanding 
of AIRE’s function and regulation thus improving our knowledge on the pathogenesis of 
APECED. In this review, we will summarize recent novelties on molecular mechanisms 
underlying the development of APECED and their clinical implications.
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inTRODUCTiOn
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), formerly known 
as autoimmune polyendocrine syndrome type 1 (APS-1), is a rare disease caused by mutations of the 
autoimmune regulator (AIRE) which acts as a transcription regulator that promotes immunological 
central tolerance (1).
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy represents a paradigm of 
genetically determined systemic autoimmunity. However, the great variability that characterizes 
APECED, irrespectively of AIRE genotype, implies that additional factors modulate the clinical 
expression of the disease.
Recent advances on how AIRE affects immunological tolerance and is linked to organ-specific 
autoimmunity have improved our understanding on the pathogenesis and the wide variability of 
clinical expression of APECED.
In this review, we will summarize new insights into AIRE genetics and functioning and its impli-
cations on APECED phenotype.
new inSiGHTS inTO AiRe FUnCTiOn
Autoimmune regulator is known to exert a crucial role in central tolerance and negative selection 
of autoreactive T cells (1). The induction of central tolerance is an intricate process that occurs 
FiGURe 1 | AiRe controls gene expression with ordered stochasticity. AIRE seems to regulate pGE in mTECs in an apparently stochastic manner. Thus, 
single mTECs would express TRAs of mixed tissue origin rather than emulating cell line age-affiliated patterns displaying the highest degree and diversity of pGE. 
Indeed, different sets of TSAs are expressed in mTECs but whether a particular AIRE-regulated TSA is expressed in a given mTEC seems to be highly probabilistic. 
The “ordered” TSA expression refers to the increased likelihood that a particular set of TSA genes will be coexpressed in an individual mTEC. Coexpressed gene loci 
tend to colocalize to the same nuclear subdomain and TSA subsets align along progressive differentiation stages within the mature mTEC subset.
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within the thymus where immature T lymphocytes are “commit-
ted” to become mature cells able to respond to a huge number 
of foreign antigens, but preventing autoimmune reactions. 
Medullary thymic epithelial cells (mTECs) have a primary role in 
the negative selection and, in this context, AIRE acts as a crucial 
transcriptional regulator. In mTECs, AIRE induces promiscuous 
gene expression (pGE) of tissue-specific antigens (TSAs), which 
are, then, presented to maturing T cells. Autoreactive T cells that 
recognize these TSAs with high affinity undergo negative selec-
tion through their apoptosis or, alternatively, regulatory T cells 
(Treg) are generated in order to prevent autoimmunity (2, 3).
Autoimmune regulator gene encodes a 545 amino acid protein 
with a molecular weight of 58 kDa (1). Starting from the amino 
terminus, AIRE is composed of a caspase recruitment domain 
(CARD)/homogeneously staining region (HSR), nuclear locali-
zation sequences (NLS), a SAND (Sp100, AIRE NucP41/75, and 
DEAF) domain, two planthomeodomain (PHD) zinc fingers, a 
proline-rich region (PRR), and four LXXLL motifs (where L stays 
for leucine) distributed among the domains (4). The CARD/HSR 
is involved in the process of AIRE homomultimerization and 
seems also to anchor AIRE to the chromatin (4, 5). The NLS has 
a stretch of basic amino acids at positions 131–133 important for 
nuclear import (4). The SAND domain does not have a distinct 
DNA-binding motif, but it is involved in promoting a protein–
protein interaction with a transcriptional repressive complex 
(6). The two AIRE PHD fingers form a structural system for the 
recruitment of chromatin-related proteins and are engaged in 
AIRE transcriptional activity (7–9). LXXLL motif and PRR are 
implicated in promoting gene transcription (4).
Autoimmune regulator has a strict spatiotemporal regula-
tion, being ubiquitously transcribed during the earliest stages of 
embryogenesis, and then restricted to thymic cells (mTECs and 
B cells) and extra thymic hematopoietic stem cells that may have 
a role in CD4 tolerization (10, 11).
At the transcriptional level, the expression of AIRE in 
mTECs and peripheral lymphoid organs is regulated by receptor 
activator of nuclear factor κB (RANK) signaling and therefore 
by nuclear factor κB (NF-κB)-induced transcription through an 
upstream conserved non-coding sequences (CNSs) of the Aire 
gene containing NF-κB-binding sites (12, 13). In addition, post-
transcriptional mechanisms seem to modulate AIRE expression. 
A dioxygenase that catalyzes lysyl hydroxylation of splicing 
regulatory proteins (Jmjd6) is critical for AIRE expression. In 
fact, the intron 2 of Aire gene is not effectively spliced out in the 
absence of Jmjd6, resulting in marked reduction of mature Aire 
protein in mTECs and spontaneous development of multi-organ 
autoimmunity in mice (14).
The AIRE protein resides inside the nucleus, where it exhibits 
a speckled localization pattern (15). AIRE is a key regulator of 
TSA expression in mTECs and affects the transcription of thou-
sands of TSA genes in a “stochastic” and “ordered” manner (16, 
17). Indeed, a small percentage (1–3%) of the total number of 
mTECs expresses a particular TSA (18). Different sets of TSAs 
are regulated by AIRE within individual mTECs but whether a 
particular AIRE-regulated TSA is expressed in a given mTEC 
seems to be highly probabilistic (18, 19). Moreover, the “ordered” 
TSA expression refers to the increased likelihood that a particular 
set of TSA genes will be coexpressed in an individual mTEC (20) 
(Figure 1).
Autoimmune regulator acts in a very unusual way among 
transcription regulators, as it has no clear DNA-binding motif but 
seems to recognize genes that possess silenced chromatin states 
(6, 8, 9, 16). AIRE does not directly initiate TSA gene transcrip-
tion, but it promotes TSA expression through the release of stalled 
RNA polymerase, RNA elongation, and splicing of target TSAs 
(15, 21). Moreover, AIRE binds to several partners that have the 
potential for post-translational protein modification, including 
the modification of AIRE itself and that seem to be critical for its 
biological function (22–24).
Recent insights on AIRE’s regulation come from experi-
mental studies which suggest that estrogen induces epigenetic 
changes in the AIRE gene, leading to reduced AIRE expression 
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under a threshold that increases susceptibility to autoimmune 
diseases (25).
In summary, induction of pGE by AIRE is dependent on a 
complex regulatory mechanism which has only been partially 
unraveled so far.
In addition to the key role exerted on pGE, AIRE seems also to 
be critical for thymic generation of Treg cells during the perinatal 
period (3, 26). However, on this issue, further work is needed (3).
Moreover, recently a new hypothesis on Aire functioning in 
tolerance has been postulated. Aire may enforce immune toler-
ance by ensuring that autoreactive T cells differentiate into the 
Treg cell lineage; dysregulation of this process results in the diver-
sion of Treg cell-biased clonotypes into pathogenic conventional 
T cells (27).
Furthermore, AIRE has several functions that are independent 
of its promotion of TSA expression in mTECs such as immu-
noregulatory functions in extrathymic AIRE-expressing cells 
and thymic B cells (15, 28). Moreover, AIRE enhances negative 
selection by regulating the repertoire of thymic dendritic cells 
and promoting apoptosis of mTECs (29, 30).
Finally, it has been postulated that AIRE regulates thymic 
maturation and architecture, probably through the expression of 
microRNAs (15, 31–34).
In summary, although our knowledge has increased in recent 
years, we still lack a coherent model incorporating and explain-
ing all the intricacies of AIRE and its role in the regulation of 
immunological tolerance.
new inSiGHTS inTO AiRe MUTATiOnS
In humans, AIRE, identified on chromosome 21q22.3 by posi-
tional cloning in 1997, consists of 14 exons spanning 11.9 kb of 
genomic DNA (15). Mutations in the AIRE gene result in the 
development of APECED, a rare autoimmune condition, but 
reported worldwide, with a higher prevalence in genetically 
isolated populations (1).
Nowadays, 101 APECED-causing mutations have been 
found throughout AIRE (http://www.hgmd.cf.ac.uk/ac/gene.
php?gene=AIRE). These mutations include nonsense/missense 
mutations, deletions, or insertions and often abolish AIRE tran-
scriptional activity or its localization to nuclear bodies (15, 35).
Despite its monogenic nature, APECED is characterized 
by a wide variability of the clinical expression and no strong 
genotype–phenotype correlation has been found among several 
populations (1, 35). Noteworthy, this lack is exemplified by the 
significant intrafamilial differences even between siblings carry-
ing the same mutation, suggesting that disease-modifying genes, 
environmental factors, and immune system dynamics may play a 
role in modulating clinical expression of the syndrome (36, 37).
Autoimmune polyendocrinopathy candidiasis ectodermal 
dystrophy has been originally considered an autosomal– recessive 
disease, and most mutations were assumed to be inherited in 
an autosomal–recessive manner, except for one mutation in the 
SAND domain, p.G228W, which exerts a dominant inheritance 
pattern (38).
However, recent evidences highlight that also heterozy-
gous mutations of the gene can be associated with increased 
susceptibility to autoimmune diseases or incomplete forms of 
APS-1 (39). Patients with atypical or incomplete manifestations 
of APECED or with other immune diseases carrying heterozy-
gous mutations of AIRE have been also described (38, 40–49). 
Cervato et al. showed different AIRE mutations in heterozygous 
state in relatives of APECED patients with various degrees of 
autoimmune or non-autoimmune diseases, but none of which 
affected by one of the major components of APECED (50).
Recently, Oftedal et al. reported a group of novel monoallelic 
and dominant-negative AIRE mutations clustered within the 
first PHD1 zinc finger domain in patients with various degrees 
of autoimmunity (39). The PHD1 domain is critical for AIRE’s 
transcription–transactivation activity and mutations in this 
domain seems to affect the structure and thus the function of 
the entire AIRE tetramer. However, the significance of these 
monoallelic mutations is still unclear since the same alterations 
were found in varying autoimmune phenotypes, ranging from 
milder phenotypes of late-onset APECED to autoimmune 
polyglandular syndrome type 2 (APS-2) and isolated organ-
specific autoimmunity following incomplete inheritance. A 
possible explanation is that AIRE tetramers still have some 
residual activity sufficient to ensure partial self-tolerance. 
Moreover, PHD1 mutations scanned in a public databases 
revealed an estimated frequency of about 0.0008, which is in 
the range of several autoimmune conditions that affect about 1 
in 1,000 people, thus suggesting that mutations in AIRE might 
be more widespread in patients with autoimmunity than previ-
ously thought (39).
Moreover, Sparks et al. identified additional dominant-negative 
AIRE mutations associated with the modulation of insulin gene 
expression in thymus which is essential to induce either insulin 
tolerance or the development of insulin autoimmunity and type 
1 diabetes (51).
APeCeD: FROM “CLASSiCAL” TO  
“nOn-CLASSiCAL” PHenOTYPe
In the light of these new knowledges, the original classification 
of APECED as unique autosomal–recessive disease seems to be 
incomplete. Taking into account the huge spectrum of pheno-
types related to AIRE mutations, Oftedal et al. interestingly pro-
posed to differentiate APECED in two major forms: (1) “classical 
APECED,” characterized by recessive inheritance, presence of at 
least two of the three main components, and interferon (IFN) 
antibodies; and (2) “non-classical APECED,” characterized by 
dominant heterozygous mutations mainly in AIRE’s PHD1 zinc 
finger and a milder, less penetrant autoimmune phenotype (39) 
(Table 1).
Classical diagnosis of APECED has been originally defined by 
the presence of two of the three most common features: chronic 
mucocutaneous candidiasis (CMC), chronic hypoparathyroidism 
(CH), and Addison’s disease (AD) (52).
Neutralizing autoantibodies against type 1 IFN (especially 
IFN-ω and IFN-α) have been found to strictly correlate with AIRE 
deficiency, thus leading to consider these autoantibodies as a pre-
cocious diagnostic tool for APECED and an additional diagnostic 
criteria for the diagnosis of APECED (52, 53). However, IFN 
TABLe 1 | APeCeD in “classical” and “non-classical” forms.
“Classical 
APeCeD”
“non-classical APeCeD”
Inheritance AR AD
Mutation Homozygous/
compound 
heterozygous
Heterozygous
Phenotype APECED 
(two of the 
three main 
components)
Various degrees of autoimmunity (from late-
onset classical APECED or APS-2 to isolated 
organ-specific autoimmunity, i.e., vitamin 
B12 deficiency, pernicious anemia, vitiligo)
Onset Childhood Childhood/adulthood
Penetrance Complete Incomplete
IFN antibodies Present Variable
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autoantibodies seem to be less prevalent in the “non-classical” 
form, probably reflecting some residual AIRE function (39).
Molecular analysis of Aire may help to confirm the 
clinical diagnosis, especially in those cases with an atypical 
presentation.
Both “classical” and “non-classical” phenotypes are character-
ized by a wide heterogeneity in the severity and in the number of 
components among affected subjects with a wide variability even 
between siblings with the same genotype (39, 54).
Chronic mucocutaneous candidiasis is the first sign to appear 
followed by CH, before the age of 10 years, and later by adrenal 
insufficiency. However, a precise chronological order is not 
always present (52).
In addition to the classic triad (CMC, CH, and AD), the phe-
notype of APECED includes several autoimmune manifestations, 
which in some cases may also precede the classical triad (52).
The spectrum of endocrinopathies associated with APECED 
includes hypergonadotropic hypogonadism, type 1 diabetes 
(T1D), autoimmune thyroid diseases (ATD), growth hormone 
(GH) deficiency, and other pituitary defects (52).
The appearance of ectodermal abnormalities is also quite com-
mon including dental enamel hypoplasia, pitted nail dystrophy, 
and alopecia. Keratopathy, vitiligo, calcifications of the tympanic 
membranes, and periodic maculopapular, morbilliform, or 
urticarial rash with fever (52) are also included in the clinical 
spectrum of APECED.
Furthermore, gastrointestinal autoimmunity in APECED 
may lead to autoimmune gastritis, autoimmune hepatitis (AIH), 
intestinal disorders with chronic diarrhea alternating with obsti-
pation, and cholelitiasis (54).
Asplenia, tubulointerstitial nephritis, interstistial lung disease 
(ILD), vasculitis, Sjogren’s syndrome, cutaneous vasculitis, hemo-
lytic anemia, scleroderma, metaphyseal dysplasia, and celiac 
disease have also been reported in APECED (55–58). Recently, 
a diagnosis of APECED was established by performing whole 
exome sequencing in a patient with increased renal echogenicity 
on renal ultrasound (59).
Muscle disease, with very similar clinical features of progres-
sive limb-girdle myopathy, is a rare component of APECED (60).
To date, two patients with APECED have been affected by 
encephalitis leading to a severe and life-threatening condition 
(61, 62).
The “non-classical” form of APECED has been suggested to 
be characterized by variable autoimmune phenotypes, ranging 
from late-onset APECED to different combinations of autoim-
mune manifestations (APS-2), isolated organ-specific autoim-
munity or autoantibodies, but no signs of autoimmune disease 
within individuals who harbor monoallelic AIRE mutations. 
In particular, families with vitamin B12 deficiency, pernicious 
anemia, and/or vitiligo at early age have been found to carry 
heterozygous PHD1 mutations, although the clinical phenotype 
has been expanded when larger materials were investigated. 
Indeed, organ-specific autoimmunity in the heterozygous cases 
seems to present in milder form and incomplete penetrance 
with respect to classical (39). These observations open a new 
window on the possibility that mutation carriers have a risk 
for developing some degree of APECED or other form of 
polyendocrinopathy.
However, more research is needed to determine the contribu-
tions of such AIRE variants to autoimmune susceptibility, espe-
cially in kindreds with a strong family history of autoimmunity.
In either “classical” or “non-classical” form of APECED, early 
diagnosis and regular surveillance, including periodic evalua-
tion of hormonal and biochemical parameters, are essential to 
allow the prevention of severe and life-threatening events (i.e., 
hypocalcemia, adrenal crisis), even in the absence of clinical 
symptoms (63).
OLD AnD new AUTOAnTiBODieS
Autoimmune polyendocrinopathy candidiasis ectodermal 
dystrophy features multi-organ autoimmunity and autoantibody 
responses against target molecules with restricted tissue expres-
sion profiles. Consequently, autoantibody markers have acquired 
a central role in research and clinical diagnosis of APECED, 
providing a tool for diagnosis, and as predicting factor for the 
clinical course of the disease.
Chronic mucocutaneous candidiasis is a sign of the underlying 
immunodeficiency. Although the pathogenesis of CMC seems to 
be different from the all other autoimmune manifestations of the 
disease, an autoimmune pathogenesis for APECED-related CMC 
has also been proposed (64). APECED patients also develop high 
titer of neutralizing autoantibodies against IL-22, IL-17F, and 
IL-17A (64). Indeed, the neutralizing autoantibodies to Th17 
cytokines or the impaired production of IL-22 and IL-17A seem 
to be associated with susceptibility to Candida infection (64).
The occurrence of endocrine manifestations is usually asso-
ciated with a specific array of organ-specific autoantibodies. 
NATCH leucine-rich repeat protein 5 (NALP5) has been identi-
fied as the target for autoimmune attack in the parathyroid cells 
(65) in APECED. Autoantibodies specific for the steroidogenic 
enzymes (CYP21A2 and CYP17A1) and side chain cleavage 
enzyme (CYP11A1) are useful markers for the autoimmune 
destruction of the adrenal cortex even years before the clini-
cal onset of the disease (5, 66). Autoantibodies to cytochrome 
CYP11A1 are associated with ovarian insufficiency (66). T1D 
is correlated with autoantibodies against insulin, IA-2 tyrosine 
phosphatase-like protein, and glutamic acid decarboxylase 
GAD65 (67).
5De Martino et al. Novel Findings into AIRE
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Autoimmune hepatitis is characterized by the presence of 
autoantibodies specific for liver-expressed cytochromes CYP1A2 
and CYP2A6 (67). Gastrointestinal symptoms have been associ-
ated with the presence of autoantibodies against tryptophan 
hydroxylase (TPH) (68). Enteroendocrine cells can also be the 
target of an autoimmune attack. Therefore, in some cases, the 
intestinal dysfunction might be viewed as an autoimmune endo-
crinopathy (69). Recently, circulating autoantibodies to Paneth 
cell-specific alpha 5 defensin and reduced numbers of Paneth 
cells in APECED patients have been reported and also associated 
with intestinal dysfunction (70).
Autoantibodies against TPH have been associated with 
alopecia, vitiligo, and enamel dysplasia and anti-SOX9/SOX10 
antibodies with vitiligo (71, 72).
Autoantibodies directed against the potassium channel 
regulatory protein (KCNRG) and BPIFB1, found in epithelial 
cells of terminal bronchioles, have been suggested as a marker 
for pulmonary disease in APECED patients (64, 73).
The autoimmune nature of renal destruction has been 
confirmed by examining biopsy samples and by determining 
antiproximal tubular autoantibodies (74, 75). Furthermore, 
autoantibodies targeting kidney collecting ducts specific antigens 
[aquaporin 2 (AQP2) and two transcription factors regulating the 
aquaporin 2 promoter, namely homolog of the human homeobox 
B7 (HOXB7) and NF of activated T cells 5 (NFAT5)], have been 
recently identified in APECED patients affected with tubuloint-
erstitial nephritis (76).
Recently, B cell response against a panel of over 9,000 human 
proteins has enabled to have a detailed profiling of known 
autoantigens and to identify novel immune targets in APECED. 
As for the lack of genotype–phenotype relationship, it has been 
shown that AIRE genotype did not appear to be an important 
determinant of autoantibody expression. Moreover, two novel 
gonadal autoantigens, melanoma antigen family B 2 (MAGEB2) 
and protein disulfide isomerase-like testis (PDILT), have been 
identified that potentially could contribute to infertility in male 
and female patients with APECED (77). Another mechanism 
proposed to explain subfertility in males with APECED is the 
presence of autoantibodies against the prostatic antigen transglu-
taminase 4 (TGM4), causing prostatitis, and possible abnormal 
sperm maturation (78).
Neutralizing autoantibodies specific for type I IFNs discov-
ered in 2006 by Meager et al. (79) are hallmark of the “classical” 
APECED and are detectable in AIRE-deficient children as early as 
a few months of age, before the appearance of clinical symptoms 
or organ-specific autoantibodies (79). Autoantibodies against 
IFN seems to be less prevalent in “non-classical” APECED, prob-
ably reflecting some residual AIRE function (39).
In conclusion, we should take into account that the autoim-
mune response in APECED appears orders of magnitude more 
limited than could be expected. There is a great discrepancy 
between the number of AIRE-controlled genes (around 4,000) 
and the number of detected autoantigens in APECED (around 
20). Several explanations must be considered. First, it could be 
that only a subset of self-antigens is able to activate autoimmune 
responses. Moreover, the peripheral tolerance mechanisms may 
provide additional filters for the development of autoimmunity. 
Finally, it has been observed that autoimmunity in APECED 
preferentially targets molecules with restricted tissue expres-
sion profiles.
new inSiGHTS inTO AiRe GeneTiCS 
AnD FUnCTiOninG: CLiniCAL 
iMPLiCATiOnS
The genetic basis of autoimmunity is a complex problem. The 
main lesson from recent evidence is that the mutations of AIRE 
can lead to various degrees of clinical autoimmunity, ranging 
from “classical” APECED to specific autoimmune conditions, 
which had not been previously mined for genetically determined 
conditions. Therefore, partial alterations of AIRE could play a 
role in common autoimmune disease; however, to measure the 
penetrance and the relative risk conferred by pathogenic AIRE 
mutations in its monoallelic variants, it will be necessary to 
sequence Aire in large cohorts of healthy individuals and autoim-
mune patients and to characterize experimentally in-depth all 
mutant alleles.
Furthermore, in the last decade, knowledge of AIRE’s function 
and regulation has been significantly expanded leading to the 
identification of several partners and regulators of AIRE. Taken 
together, these molecular insights open new perspectives in 
understanding the phenotypic variability related to AIRE muta-
tions and might provide interesting targets for novel therapeutic 
approach.
Indeed, an unanimously accepted effective therapy for 
APECED is not currently available. The use of immunosup-
pressive treatment in this category of patients may lead to a 
transient immunodeficiency with the risk to worsen their CMC 
and seems not able to stop the progression of all APECED 
manifestations (80). Thus, the management is mainly based on 
the care of each individual component and is mainly character-
ized by substitutive treatments for hormone deficiencies and 
immunomodulators have been only used in selected severe 
phenotypes (80, 81).
Although thymic transplantation has been proven useful in 
the treatment of differentiative thymic disorder (82), no data 
are available on this intervention on alterations of the thymic 
negative selection process. Thymic compartment can be targeted 
to modulate immune tolerance, for example, by enhancing 
AIRE expression, promoting deletion of self-reactive T cells and 
enhancing positive Treg cell selection, or inducing differentiation 
of TECs from pluripotent stem cells, offering new exciting pos-
sibility in therapeutic manipulation (15).
In conclusions, the new insights in the biology of AIRE and 
its control in immune tolerance offer exciting possibilities for the 
exploration of diagnostic and therapeutic strategies that would 
benefit APECED patients.
AUTHOR COnTRiBUTiOnS
All the authors contributed equally to this work.
6De Martino et al. Novel Findings into AIRE
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 86
ReFeRenCeS
1. Abramson J, Husebye ES. Autoimmune regulator and self-tolerance – 
molecular and clinical aspects. Immunol Rev (2016) 271(1):127–40. 
doi:10.1111/imr.12419 
2. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection 
of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol 
(2014) 14(6):377–91. doi:10.1038/nri3667 
3. Yang S, Fujikado N, Kolodin D, Benoist C, Mathis D. Immune tolerance. 
Regulatory T cells generated early in life play a distinct role in maintain-
ing  self-tolerance. Science (2015) 348(6234):589–94. doi:10.1126/science. 
aaa7017 
4. Perniola R, Musco G. The biophysical and biochemical properties of 
the autoimmune regulator (AIRE) protein. Biochim Biophys Acta (2014) 
1842(2):326–37. doi:10.1016/j.bbadis.2013.11.020 
5. Maslovskaja J, Saare M, Liiv I, Rebane A, Peterson P. Extended HSR/CARD 
domain mediates AIRE binding to DNA. Biochem Biophys Res Commun 
(2015) 468(4):913–20. doi:10.1016/j.bbrc.2015.11.056 
6. Waterfield M, Khan IS, Cortez JT, Fan U, Metzger T, Greer A, et  al. The 
transcriptional regulator Aire coopts the repressive ATF7ip-MBD1 complex 
for the induction of immunotolerance. Nat Immunol (2014) 15(3):258–65. 
doi:10.1038/ni.2820 
7. Gaetani M, Matafora V, Saare M, Spiliotopoulos D, Mollica L, Quilici G, 
et  al. AIRE-PHD fingers are structural hubs to maintain the integrity of 
chromatin-associated interactome. Nucleic Acids Res (2012) 40(22):11756–68. 
doi:10.1093/nar/gks933 
8. Org T, Chignola F, Hetényi C, Gaetani M, Rebane A, Liiv I, et al. The auto-
immune regulator PHD finger binds to non-methylated histone H3K4 to 
activate gene expression. EMBO Rep (2008) 9(4):370–6. doi:10.1038/sj.embor. 
2008.11 
9. Koh AS, Kuo AJ, Park SY, Cheung P, Abramson J, Bua D, et al. Aire employs 
a histone-binding module to mediate immunological tolerance, linking 
chromatin regulation with organ-specific autoimmunity. Proc Natl Acad Sci 
U S A (2008) 105(41):15878–83. doi:10.1073/pnas.0808470105 
10. Poliani PL, Kisand K, Marrella V, Ravanini M, Notarangelo LD, Villa A, 
et  al. Human peripheral lymphoid tissues contain autoimmune regulator- 
expressing dendritic cells. Am J Pathol (2010) 176(3):1104–12. doi:10.2353/
ajpath.2010.090956 
11. Gardner JM, Metzger TC, McMahon EJ, Au-Yeung BB, Krawisz AK, Lu W, 
et al. Extrathymic Aire-expressing cells are a distinct bone marrow-derived 
population that induce functional inactivation of CD4+ T cells. Immunity 
(2013) 39(3):560–72. doi:10.1016/j.immuni.2013.08.005 
12. Haljasorg U, Bichele R, Saare M, Guha M, Maslovskaja J, Kõnd K, et  al.  
A highly conserved NF-κB-responsive enhancer is critical for thymic expres-
sion of Aire in mice. Eur J Immunol (2015) 45(12):3246–56. doi:10.1002/eji. 
201545928 
13. LaFlam TN, Seumois G, Miller CN, Lwin W, Fasano KJ, Waterfield M, et al. 
Identification of a novel cis-regulatory element essential for immune toler-
ance. J Exp Med (2015) 212(12):1993–2002. doi:10.1084/jem.20151069 
14. Yanagihara T, Sanematsu F, Sato T, Uruno T, Duan X, Tomino T, et al. Intronic 
regulation of Aire expression by Jmjd6 for self-tolerance induction in the 
thymus. Nat Commun (2015) 6:8820. doi:10.1038/ncomms9820 
15. Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and 
beyond. Nat Rev Immunol (2016) 16(4):247–58. doi:10.1038/nri.2016.9 
16. Sansom SN, Shikama-Dorn N, Zhanybekova S, Nusspaumer G, Macaulay 
IC, Deadman ME, et  al. Population and single-cell genomics reveal the 
Aire dependency, relief from polycomb silencing, and distribution of self- 
antigen expression in thymic epithelia. Genome Res (2014) 24(12):1918–31. 
doi:10.1101/gr.171645.113 
17. Meredith M, Zemmour D, Mathis D, Benoist C. Aire controls gene expression 
in the thymic epithelium with ordered stochasticity. Nat Immunol (2015) 
16(9):942–9. doi:10.1038/ni.3247 
18. Derbinski J, Pinto S, Rösch S, Hexel K, Kyewski B. Promiscuous gene expres-
sion patterns in single medullary thymic epithelial cells argue for a stochastic 
mechanism. Proc Natl Acad Sci U S A (2008) 105(2):657–62. doi:10.1073/
pnas.0707486105 
19. Villaseñor J, Besse W, Benoist C, Mathis D. Ectopic expression of peripheral- 
tissue antigens in the thymic epithelium: probabilistic, monoallelic, 
misinitiated. Proc Natl Acad Sci U S A (2008) 105(41):15854–9. doi:10.1073/
pnas.0808069105 
20. Pinto S, Michel C, Schmidt-Glenewinkel H, Harder N, Rohr K, Wild S, 
et  al. Overlapping gene coexpression patterns in human medullary thymic 
epithelial cells generate self-antigen diversity. Proc Natl Acad Sci U S A (2013) 
110(37):E3497–505. doi:10.1073/pnas.1308311110 
21. Giraud M, Yoshida H, Abramson J, Rahl PB, Young RA, Mathis D, et  al. 
Aire unleashes stalled RNA polymerase to induce ectopic gene expression 
in thymic epithelial cells. Proc Natl Acad Sci U S A (2012) 109(2):535–40. 
doi:10.1073/pnas.1119351109 
22. Incani F, Serra M, Meloni A, Cossu C, Saba L, Cabras T, et al. AIRE acetylation 
and deacetylation: effect on protein stability and transactivation activity. 
J Biomed Sci (2014) 21:85. doi:10.1186/s12929-014-0085-z 
23. Chuprin A, Avin A, Goldfarb Y, Herzig Y, Levi B, Jacob A, et al. The deacetylase 
Sirt1 is an essential regulator of Aire-mediated induction of central immu-
nological tolerance. Nat Immunol (2015) 16(7):737–45. doi:10.1038/ni.3194 
24. Rattay K, Claude J, Rezavandy E, Matt S, Hofmann TG, Kyewski B, et  al. 
Homeodomain-interacting protein kinase 2, a novel autoimmune regulator 
interaction partner, modulates promiscuous gene expression in medullary 
thymic epithelial cells. J Immunol (2015) 194(3):921–8. doi:10.4049/
jimmunol.1402694 
25. Dragin N, Bismuth J, Cizeron-Clairac G, Biferi MG, Berthault C, Serraf A, 
et  al. Estrogen-mediated downregulation of AIRE influences sexual 
dimorphism in autoimmune diseases. J Clin Invest (2016) 126(4):1525–37. 
doi:10.1172/JCI81894 
26. Leventhal DS, Gilmore DC, Berger JM, Nishi S, Lee V, Malchow S, et  al. 
Dendritic cells coordinate the development and homeostasis of organ-spe-
cific regulatory T cells. Immunity (2016) 44(4):847–59. doi:10.1016/j.
immuni.2016.01.025 
27. Malchow S, Leventhal DS, Lee V, Nishi S, Socci ND, Savage PA. Aire enforces 
immune tolerance by directing autoreactive T cells into the regulatory 
T  cell lineage. Immunity (2016) 44(5):1102–13. doi:10.1016/j.immuni.2016. 
02.009 
28. Yamano T, Nedjic J, Hinterberger M, Steinert M, Koser S, Pinto S, et al. Thymic 
B cells are licensed to present self antigens for central T cell tolerance induc-
tion. Immunity (2015) 42(6):1048–61. doi:10.1016/j.immuni.2015.05.013 
29. Lei Y, Ripen AM, Ishimaru N, Ohigashi I, Nagasawa T, Jeker LT, et al. Aire-
dependent production of XCL1 mediates medullary accumulation of thymic 
dendritic cells and contributes to regulatory T cell development. J Exp Med 
(2011) 208(2):383–94. doi:10.1084/jem.20102327 
30. Gray D, Abramson J, Benoist C, Mathis D. Proliferative arrest and rapid 
turnover of thymic epithelial cells expressing Aire. J Exp Med (2007) 
204(11):2521–8. doi:10.1084/jem.20070795 
31. Matsumoto M, Nishikawa Y, Nishijima H, Morimoto J, Matsumoto M, 
Mouri Y. Which model better fits the role of aire in the establishment of self- 
tolerance: the transcription model or the maturation model? Front Immunol 
(2013) 22(4):210. doi:10.3389/fimmu.2013.00210 
32. Macedo C, Oliveira EH, Almeida RS, Donate PB, Fornari TA, Pezzi N, et al. 
Aire-dependent peripheral tissue antigen mRNAs in mTEC cells feature 
networking refractoriness to microRNA interaction. Immunobiology (2015) 
220(1):93–102. doi:10.1016/j.imbio.2014.08.015 
33. Kisand K, Peterson P, Laan M. Lymphopenia-induced proliferation in 
aire-deficient mice helps to explain their autoimmunity and differences 
from human patients. Front Immunol (2014) 5:51. doi:10.3389/fimmu.2014. 
00051 
34. Nishikawa Y, Nishijima H, Matsumoto M, Morimoto J, Hirota F, Takahashi S, 
et al. Temporal lineage tracing of Aire-expressing cells reveals a requirement 
for Aire in their maturation program. J Immunol (2014) 192(6):2585–92. 
doi:10.4049/jimmunol.1302786 
35. Capalbo D, Mazza C, Giordano R, Improda N, Arvat E, Cervato S, 
et  al. Mole cular background and genotype-phenotype correlation in 
 autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy 
patients from Campania and in their relatives. J Endocrinol Invest (2012) 
35(2):169–73. doi:10.3275/7677 
36. Capalbo D, De Martino L, Giardino G, Di Mase R, Di Donato I, Parenti G, et al. 
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: insights 
into genotype-phenotype correlation. Int J Endocrinol (2012) 2012:353250. 
doi:10.1155/2012/353250 
7De Martino et al. Novel Findings into AIRE
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 86
37. De Martino L, Capalbo D, Improda N, D’Elia F, Di Mase R, D’Assante R, 
et  al. APECED: a paradigm of complex interactions between genetic back-
ground and susceptibility factors. Front Immunol (2013) 4:331. doi:10.3389/
fimmu.2013.00331 
38. Cetani F, Barbesino G, Borsari S, Pardi E, Cianferotti L, Pinchera A, et  al. 
A  novel mutation of the autoimmune regulator gene in an Italian kindred 
with autoimmune polyendocrinopathy-candidiasis-ectoderma dystrophy, 
acting in a dominant fashion and strongly consegregating with hypothy-
roid autoimmune thyroiditis. J Clin Endocrinol Metab (2001) 86:4747–52. 
doi:10.1210/jc.86.10.4747 
39. Oftedal BE, Hellesen A, Erichsen MM, Bratland E, Vardi A, Perheentupa J, 
et  al. Dominant mutations in the autoimmune regulator AIRE are associ-
ated with common organ-specific autoimmune diseases. Immunity (2015) 
42(6):1185–96. doi:10.1016/j.immuni.2015.04.021 
40. Söderbergh A, Rorsman F, Halonen M, Ekwall O, Björses P, Kämpe O, et al. 
Autoantibodies against aromatic l-amino acid decarboxylase identifies a 
subgroup of patients with Addison’s disease. J Clin Endocrinol Metab (2000) 
85(1):460–3. doi:10.1210/jc.85.1.460 
41. Boe A, Knappskog M, Myhre A, Sørheim JI, Husebye ES. Mutational analysis 
of the autoimmune regulator (AIRE) gene in sporadic autoimmune Addison’s 
disease can reveal patients with unidentified autoimmune polyendocrine 
syndrome type 1. Eur J Endocrinol (2002) 146:519–22. doi:10.1530/eje.0. 
1460519 
42. Buzi F, Badolato R, Mazza C, Giliani S, Notarangelo LD, Radetti G, et al. Auto-
immune polyendogrinopathy-candidiasis-ectodermal dystrophy syndrome: 
time to review diagnostic criteria? J Clin Endocrinol Metab (2003) 88:3146–8. 
doi:10.1210/jc.2002-021495 
43. Ferrera F, Rizzi M, Sprecacenere B, Balestra P, Sessarego M, Di Carlo A, et al. 
AIRE gene polymorphisms in systemic sclerosis associated with autoimmune 
thyroiditis. Clin Immunol (2007) 122:13–7. doi:10.1016/j.clim.2006.09.013 
44. Lankisch TO, Mourier O, Sokal EM, Habes D, Lacaille F, Bridoux-Henno L, 
et  al. AIRE gene analysis in children with autoimmune hepatitis type I or 
II. J Pediatr Gastroenterol Nutr (2009) 48(4):498–500. doi:10.1097/MPG. 
0b013e31818550de 
45. Meyer G, Donner H, Herwig J, Böhles H, Usadel KH, Badenhoop K. Screening 
for an AIRE-1 mutation in patients with Addison’s disease, type 1 diabetes, 
Graves’ disease and Hashimoto’s thyroiditis as well as in APECED syndrome. 
Clin Endocrinol (Oxf) (2001) 54(3):335–8. doi:10.1046/j.1365-2265.2001. 
01230.x 
46. Zhang J, Liu H, Liu Z, Liao Y, Guo L, Wang H, et al. A functional alternative 
splicing mutation in AIRE gene causes autoimmune polyendocrine syndrome 
type 1. PLoS One (2013) 8(1):e53981. doi:10.1371/journal.pone.0053981 
47. Bellacchio E, Palma A, Corrente S, Di Girolamo F, Helen Kemp E, Di Matteo 
G, et  al. The possible implication of the S250C variant of the autoimmune 
regulator protein in a patient with autoimmunity and immunodeficiency: 
in silico analysis suggests a molecular pathogenic mechanism for the variant. 
Gene (2014) 549(2):286–94. doi:10.1016/j.gene.2014.07.064 
48. Tsai SL, Green J, Metherell LA, Curtis F, Fernandez B, Healey A, et al. Primary 
adrenocortical insufficiency case series: genetic etiologies more common than 
expected. Horm Res Paediatr (2016) 85(1):35–42. doi:10.1159/000441843 
49. Cervato S, Morlin L, Albergoni MP, Masiero S, Greggio N, Meossi C, et al. 
AIRE gene mutations and autoantibodies to interferon omega in patients with 
chronic hypoparathyroidism without APECED. Clin Endocrinol (Oxf) (2010) 
73:630–6. doi:10.1111/j.1365-2265.2010.03862.x 
50. Cervato S, Mariniello B, Lazzarotto F, Morlin L, Zanchetta R, Radetti G, et al. 
Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of 
Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectoder-
mal-dystrophy (APECED) and in their relatives. Clin Endocrinol (Oxf) (2009) 
70(3):421–8. doi:10.1111/j.1365-2265.2008.03318.x 
51. Sparks AE, Chen C, Breslin MB, Lan MS. Functional domains of autoimmune 
regulator, AIRE, modulate INS-VNTR transcription in human thymic 
epithelial cells. J Biol Chem (2016) 291(21):11313–22. doi:10.1074/jbc.M116. 
722488 
52. Husebye ES, Perheentupa J, Rautemaa R, Kampe O. Clinical manifestations 
and management of patients with autoimmune polyendocrine syndrome 
type I. J Intern Med (2009) 265:514–29. doi:10.1111/j.1365-2796.2009.02090.x 
53. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, et  al. 
Autoantibodies against type I interferons as an additional diagnostic criterion 
for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 
(2008) 93:4389–97. doi:10.1210/jc.2008-0935 
54. Capalbo D, Fusco A, Aloj G, Improda N, Vitiello L, Dianzani U, et al. High 
intrafamilial variability in autoimmune polyendocrinopathy-candidiasis- 
ectodermal dystrophy: a case study. J Endocrinol Invest (2012) 35(1):77–81. 
doi:10.3275/8055 
55. Friedman TC, Thomas PM, Fleisher TA, Feuillan P, Parker RI, Cassorla F, 
et  al. Frequent occurrence of asplenism and cholelithiasis in patients with 
autoimmune polyglandular disease type I. Am J Med (1991) 91(6):625–30. 
doi:10.1016/0002-9343(91)90215-J 
56. Orlova EM, Bukina AM, Kuznetsova ES, Kareva MA, Zakharova EU, 
Peterkova VA, et al. Autoimmune polyglandular syndrome type 1 in Russian 
patients: clinical variants and autoimmune regulator mutations. Horm Res 
Paediatr (2010) 73(6):449–57. doi:10.1159/000313585 
57. Betterle C, Greggio NA, Volpato M. Clinical review 93: autoimmune poly-
glandular syndrome type 1. J Clin Endocrinol Metab (1998) 83(4):1049–55. 
doi:10.1210/jcem.83.4.4682 
58. Improda N, Capalbo D, Cirillo E, Cerbone M, Esposito A, Pignata C, et al. 
Cutaneous vasculitis in patients with autoimmune polyendocrine syndrome 
type 1: report of a case and brief review of the literature. BMC Pediatr (2014) 
14:272. doi:10.1186/1471-2431-14-272 
59. Braun DA, Schueler M, Halbritter J, Gee HY, Porath JD, Lawson JA, et  al. 
Whole exome sequencing identifies causative mutations in the majority of 
consanguineous or familial cases with childhood-onset increased renal echo-
genicity. Kidney Int (2016) 89(2):468–75. doi:10.1038/ki.2015.317 
60. Watanabe M, Ochi H, Arahata H, Matsuo T, Nagafuchi S, Ohyagi Y, et  al. 
Myopathy in autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy. Muscle Nerve (2012) 45(6):904–8. doi:10.1002/mus.23321 
61. Capalbo D, Elefante A, Spagnuolo MI, Mazza C, Betterle C, Pignata C, 
et  al. Posterior reversible encephalopathy syndrome in a child during 
an accelerated phase of a severe APECED phenotype due to an uncom-
mon mutation of AIRE. Clin Endocrinol (Oxf) (2008) 69(3):511–3. 
doi:10.1111/j.1365-2265.2008.03206.x 
62. Mazza C, Buzi F, Ortolani F, Vitali A, Notarangelo LD, Weber G, et al. Clinical 
heterogeneity and diagnostic delay of autoimmune polyendocrinopathy- 
candidiasis-ectodermal dystrophy syndrome. Clin Immunol (2011) 139(1): 
6–11. doi:10.1016/j.clim.2010.12.021 
63. Capalbo D, Improda N, Esposito A, De Martino L, Barbieri F, Betterle C, 
et  al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
from the pediatric perspective. J Endocrinol Invest (2013) 36(10):903–12. 
doi:10.3275/8999 
64. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. 
Chronic mucocutaneous candidiasis in APECED or thymoma patients cor-
relates with autoimmunity to Th17-associated cytokines. J Exp Med (2010) 
207:299–308. doi:10.1084/jem.20091669 
65. Alimohammadi M, Dubois N, Skoldberg F, Hallgren A, Tardivel I, 
Hedstrand  H, et  al. Pulmonary autoimmunity as a feature of autoimmune 
polyendocrine syndrome type 1 and identification of KCNRG as a bronchial 
autoantigen. Proc Natl Acad Sci U S A (2009) 106:4396–401. doi:10.1073/
pnas.0809986106 
66. Soderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand H, Landgren 
E, et al. Prevalence and clinical associations of 10 defined autoantibodies in 
autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab (2004) 
89:557–62. doi:10.1210/jc.2003-030279 
67. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis 
S. Two cytochromes P450 are major hepatocellular autoantigens in autoim-
mune polyglandular syndrome type 1. Gastroenterology (1998) 114(2):324–8. 
doi:10.1016/S0016-5085(98)70484-6 
68. Ekwall O, Hedstrand H, Grimelius L, Haavik J, Perheentupa J, Gustafsson J, 
et  al. Identification of tryptophan hydroxylase as an intestinal autoantigen. 
Lancet (1998) 352(9124):279–83. doi:10.1016/S0140-6736(97)11050-9 
69. Gianani R, Eisenbarth GS. Autoimmunity to gastrointestinal endocrine cells 
in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 
(2003) 88(4):1442–4. doi:10.1210/jc.2003-030247 
70. Dobeš J, Neuwirth A, Dobešová M, Vobořil M, Balounová J, Ballek O, et al. 
Gastrointestinal autoimmunity associated with loss of central tolerance to 
enteric α-defensins. Gastroenterology (2015) 149(1):139–50. doi:10.1053/j.
gastro.2015.05.009 
8De Martino et al. Novel Findings into AIRE
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 86
71. Bratland E, Magitta NF, Boe Wolff AS, Ekern T, Knappskog PM, Kampe O, 
et  al. Autoantibodies against aromatic amino acid hydroxylases in patients 
with autoimmune polyendocrine syndrome type 1 target multiple antigenic 
determinants and reveal regulatory regions crucial for enzymatic activity. 
Immunobiology (2013) 218:899–909. doi:10.1016/j.imbio.2012.10.006 
72. Hedstrand H, Ekwall O, Olsson MJ, Landgren E, Kemp EH, Weetman AP, et al. 
The transcription factors SOX9 and SOX10 are vitiligo autoantigens in auto-
immune polyendocrine syndrome type I. J Biol Chem (2001) 276:35390–5. 
doi:10.1074/jbc.M102391200 
73. Shum AK, Alimohammadi M, Tan CL, Cheng MH, Metzger TC, Law CS, et al. 
BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. 
Sci Transl Med (2014) 5:206ra139. doi:10.1126/scitranslmed.3006998 
74. Ulinski T, Perrin L, Morris M, Houang M, Cabrol S, Grapin C, et  al. 
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syn-
drome with renal failure: impact of posttransplant immunosuppression on 
disease activity. J Clin Endocrinol Metab (2006) 91(1):192–5. doi:10.1210/jc. 
2005-1538 
75. Al-Owain M, Kaya N, Al-Zaidan H, Bin Hussain I, Al-Manea H, Al-Hindi H, 
et al. Renal failure associated with APECED and terminal 4q deletion: evi-
dence of autoimmune nephropathy. Clin Dev Immunol (2010) 2010:586342. 
doi:10.1155/2010/586342 
76. Landegren N, Lindberg MP, Skov J, Hallgren Å, Eriksson D, Lisberg Toft-
Bertelsen T, et  al. Autoantibodies targeting a collecting duct specific water 
channel in tubulointerstitial nephritis. J Am Soc Nephrol (2016). doi:10.1681/
ASN.2015101126
77. Landegren N, Sharon D, Freyhult E, Hallgren Å, Eriksson D, Edqvist PH, 
et al. Proteome-wide survey of the autoimmune target repertoire in autoim-
mune polyendocrine syndrome type 1. Sci Rep (2016) 6:20104. doi:10.1038/
srep20104 
78. Landegren N, Sharon D, Shum AK, Khan IS, Fasano KJ, Hallgren Å, et  al. 
Transglutaminase 4 as a prostate autoantigen in male subfertility. Sci Transl 
Med (2015) 7(292):292ra101. doi:10.1126/scitranslmed.aaa9186 
79. Meager A, Visvalingam K, Peterson P, Möll K, Murumägi A, Krohn K, et al. 
Anti-interferon autoantibodies in autoimmune polyendocrinopathy syn-
drome type 1. PLoS Med (2006) 3:e289. doi:10.1371/journal.pmed.0030289 
80. Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis 
ectodermal dystrophy. J Clin Immunol (2015) 35(5):463–78. doi:10.1007/
s10875-015-0176-y 
81. Capalbo D, Giardino G, Martino LD, Palamaro L, Romano R, Gallo V, et al. 
Genetic basis of altered central tolerance and autoimmune diseases: a lesson 
from AIRE mutations. Int Rev Immunol (2012) 31(5):344–62. doi:10.3109/08
830185.2012.697230 
82. Markert ML, Marques JG, Neven B, Devlin BH, McCarthy EA, Chinn IK, 
et  al. First use of thymus transplantation therapy for FOXN1 deficiency 
(nude/SCID): a report of 2 cases. Blood (2011) 117(2):688–96. doi:10.1182/
blood-2010-06-292490 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 De Martino, Capalbo, Improda, Lorello, Ungaro, Di Mase, Cirillo, 
Pignata and Salerno. This is an open-access article distributed under the terms of 
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
